Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.

Tobinai K, Takahashi T, Akinaga S.

Curr Hematol Malig Rep. 2012 Sep;7(3):235-40. doi: 10.1007/s11899-012-0124-3. Review.

2.

Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.

Remer M, Al-Shamkhani A, Glennie M, Johnson P.

Immunotherapy. 2014;6(11):1187-206. doi: 10.2217/imt.14.94. Review.

PMID:
25496334
3.

Clinical Application of Anti-CCR4 Monoclonal Antibody.

Ueda R.

Oncology. 2015;89 Suppl 1:16-21. doi: 10.1159/000431059. Epub 2015 Nov 10. Review.

PMID:
26550987
4.

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.

de Lartigue J.

Drugs Today (Barc). 2012 Oct;48(10):655-60. doi: 10.1358/dot.2012.48.10.1885878. Review.

PMID:
23110261
5.

Recent advances in the treatment of adult T-cell leukemia-lymphomas.

Utsunomiya A, Choi I, Chihara D, Seto M.

Cancer Sci. 2015 Apr;106(4):344-51. doi: 10.1111/cas.12617. Epub 2015 Mar 6. Review.

6.

[Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].

Iida S, Ishida T, Ueda R.

Yakugaku Zasshi. 2015;135(5):663-9. doi: 10.1248/yakushi.14-00230-3. Review. Japanese.

7.

CCR4 and its ligands: from bench to bedside.

Yoshie O, Matsushima K.

Int Immunol. 2015 Jan;27(1):11-20. doi: 10.1093/intimm/dxu079. Epub 2014 Aug 2. Review.

PMID:
25087232
8.

[Development of an anti-CCR4 antibody, mogamulizumab, the first approved antibody made by POTELLIGENT(®) technology].

Ishii T.

Nihon Yakurigaku Zasshi. 2013 Oct;142(4):167-71. Review. Japanese. No abstract available.

PMID:
24107520
9.

Biology and treatment of HTLV-1 associated T-cell lymphomas.

Tsukasaki K, Tobinai K.

Best Pract Res Clin Haematol. 2013 Mar;26(1):3-14. doi: 10.1016/j.beha.2013.04.001. Epub 2013 May 23. Review.

PMID:
23768636
10.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
11.

Immunopathogenesis of lymphoma: focus on CCR4.

Ishida T, Ueda R.

Cancer Sci. 2011 Jan;102(1):44-50. doi: 10.1111/j.1349-7006.2010.01767.x. Epub 2010 Nov 2. Review.

12.

Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.

Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S.

Crit Rev Oncol Hematol. 2016 Mar;99:214-27. doi: 10.1016/j.critrevonc.2015.12.016. Epub 2016 Jan 3. Review.

13.

Therapeutic options for adult T-cell leukemia/lymphoma.

Marçais A, Suarez F, Sibon D, Frenzel L, Hermine O, Bazarbachi A.

Curr Oncol Rep. 2013 Oct;15(5):457-64. doi: 10.1007/s11912-013-0332-6. Review.

PMID:
23943384
14.

The role of alemtuzumab in the management of T-cell malignancies.

Dearden C.

Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52. Review.

PMID:
16720203
15.

Expression of CCR4 in adult T-cell leukemia.

Yoshie O.

Leuk Lymphoma. 2005 Feb;46(2):185-90. Review.

PMID:
15621800
16.

[Leukemia: recent progress in diagnosis and treatment. Topics: IV. Recent topics; 1. Novel antibody therapy targeting CCR4 for adult T-cell leukemia/lymphoma].

Ishida T.

Nihon Naika Gakkai Zasshi. 2013 Jul 10;102(7):1744-50. Review. Japanese. No abstract available.

PMID:
23947237
18.

Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.

Zinzani PL, Corradini P, Gallamini A, Grossi A, Lazzarino M, Marchetti M, Martelli M, Rossi G, Vitolo U.

Leuk Lymphoma. 2012 May;53(5):789-95. doi: 10.3109/10428194.2011.629701. Epub 2011 Nov 18. Review.

PMID:
21980956
19.

Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.

Tobinai K.

Semin Hematol. 2010 Apr;47 Suppl 1:S5-7. doi: 10.1053/j.seminhematol.2010.01.015. Review.

PMID:
20359583
20.

Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?

Iqbal J, Wilcox R, Naushad H, Rohr J, Heavican TB, Wang C, Bouska A, Fu K, Chan WC, Vose JM.

Blood Rev. 2016 Mar;30(2):89-100. doi: 10.1016/j.blre.2015.08.003. Epub 2015 Aug 18. Review.

PMID:
26319391

Supplemental Content

Support Center